Targeting tumor specific antigens with modified gB, or with the other modified envelope glycoproteins, does not theoretically address the issue of tumor heterogeneity, which is considered a common cause of treatment failure for targeted therapy. This evidence concerns the gene ERVW-1 and neoplasm.